查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990216

DNA修復藥物市場：2026-2032年全球市場預測（依藥物類別、作用機制、適應症、給藥途徑及最終用戶分類）

DNA Repair Drugs Market by Drug Class, Mechanism Of Action, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

DNA修復療法市場預計到2025年將達到98.7億美元，到2026年將成長到105.3億美元，到2032年將達到163.1億美元，複合年成長率為7.43%。

主要市場統計數據
基準年 2025 98.7億美元
預計年份：2026年 105.3億美元
預測年份 2032 163.1億美元
複合年成長率 (%) 7.43%

全面概述了現代腫瘤學中DNA修復療法的科學進展、法規環境和商業性需求。

DNA修復療法領域融合了分子生物學、精準腫瘤學和新型藥物技術，共同重塑了多種腫瘤的治療方法。近年來，隨著對腫瘤基因組學和合成致死機制的深入理解，靶向DNA損害反應路徑的治療方法已從學術研究發展成為特定適應症的臨床常用療法。目前，該領域既包括已開發的藥物類別，也包括利用癌細胞新發現的脆弱性而研發的新型抑制劑。

基因組精準醫療、適應性臨床試驗和聯合策略如何重塑 DNA 修復療法的研發重點和商業模式。

DNA修復療法生態系統正經歷變革性的變化，這些變化正在改變研發重點、臨床試驗設計和商業模式。基因組分析和生物標記檢驗的進步迫使研發人員設計分子選擇性和適應性試驗，從而能夠快速識別有效患者，同時減少無效患者的暴露。同時，DNA修復抑制劑與免疫療法、標靶治療或傳統細胞毒性藥物的聯合治療策略正從探索性方案走向系統性開發路徑，反映出一種向多模態治療方法的策略調整。

2025 年關稅趨勢對全球藥品供應鏈、研發進度以及 DNA 修復療法取得策略的影響。

2025年宣布或實施的涉及關稅措施的政策轉變，重新引發了人們對醫藥原料和成品跨境供應鏈的關注。由於許多DNA修復療法依賴特殊的活性成分、複雜的化學合成以及進口的實驗室耗材，關稅帶來的成本壓力可能會影響生產經濟效益和臨床供應的物流。為此，各公司正在重新評估供應商多元化策略，盡可能將關鍵生產流程遷回國內市場，並協商長期採購協議以降低價格波動。

詳細的細分市場特定要求，展示了藥物類別、作用機制、適應症、給藥途徑和最終用戶趨勢如何結合起來，形成獨特的開發和商業化策略。

細分市場層面的洞察揭示了不同作用機制、適應症、給藥途徑和終端用戶群中獨特的研發路徑和商業性考量，這些因素共同決定了投資重點。從藥物類別來看，競爭格局和臨床趨勢涵蓋了ATM抑制劑、ATR抑制劑、 DNA甲基轉移酵素抑制劑、HDAC抑制劑和PARP抑制劑。在這些類別中， DNA甲基轉移酵素抑制劑又可分為已上市藥物和研究藥物。而PARP抑制劑則構成了一個多層次的市場，包含品牌學名藥和正在研發的新藥，影響著定價和市場定位策略。這種多樣性要求在藥物生命週期的各個階段採取差異化策略。已上市藥物需要拓展適應症並累積真實世界數據（REW）；在研藥物需要進行轉化檢驗並建立策略聯盟；而學名藥需要採取專注於擴大市場准入和銷售量的策略。

基於監管、報銷和基礎設施現實的區域策略差異，決定了臨床開發重點和市場進入方式。

區域趨勢對DNA修復療法的研發、監管溝通和商業化等各環節的策略決策都有顯著影響。在美洲，尤其注重快速與監管機構溝通、為支付方提供證據，並優先考慮主導生物標記為導向的適應症。臨床試驗網路和腫瘤聯盟為後期評估和真實世界數據（REW）的收集提供了強大的支持。歐洲、中東和非洲（EMEA）地區的情況則更為複雜，監管協調程度不同、報銷機制各異以及醫療基礎設施差異較大，因此需要製定針對特定區域的市場准入計劃和差異化定價策略。製造商通常會根據衛生技術評估（HTA）框架以及集中式或分散式的報銷機制，優先選擇這些區域內的國家進行早期上市。

為了加速推廣應用，領先的研發公司正專注於以夥伴關係、診斷整合、強大的供應鏈和主導商業化為重點的企業策略。

DNA修復療法領域的主要企業正展現出通用的策略性舉措：具體而言，包括建立合作夥伴關係以拓展聯合治療，投資伴隨診斷研發以支持精準的患者篩選，以及開展有針對性的併購和許可活動以強化互補資產。大型製藥企業正日益與生物技術公司合作，以加速轉化科學發展並確保獲得新型化學結構和專有生物標記平台。同時，靈活的生技公司正利用早期概念驗證資料來共同開發契約，並獲得III期臨床試驗的資金，從而建構一個以互補能力和風險共用為核心的生態系統，推動研發進展。

明確且可操作的經營團隊重點，以整合生物標記主導的證據、穩健的運作和有針對性的商業化，從而推進 DNA 修復計劃。

產業領導者應優先考慮一系列切實可行的舉措，將科學潛力轉化為永續的商業性成功。首先，將生物標記策略和衛生經濟學納入早期研發計劃，確保臨床試驗結果符合支付者的預期和臨床決策。這將有助於申辦方降低市場進入門檻，並在產品上市時提升其價值提案。其次，尋求策略聯盟，將互補的作用機制和治療方法結合，以增強聯合治療的合理性，並分散整個研發組合的風險。

採用穩健的多方法研究設計，結合專家訪談、全面的二手資訊和三角測量分析技術，以確保有效性和透明度。

本研究採用結構化、多維度的方法整合數據，結合一級資訊來源和二級資訊來源，以確保洞察的廣度和深度。一手研究包括對腫瘤領域關鍵意見領袖（KOL）、大中小型生物製藥公司高管、監管專家和市場進入負責人，從而獲取關於臨床開發、監管預期和商業化挑戰的細緻觀點。二手研究涵蓋同行評審文獻、臨床試驗註冊數據、監管申報、專利趨勢和公司資訊披露，並採用三角檢驗對研究結果進行分析，以檢驗戰略趨勢。

結論強調，協調機制創新、證據產生和營運韌性對於實現永續的臨床和商業性影響至關重要。

總之，DNA修復療法在腫瘤學領域中佔據著一個至關重要且快速發展的細分市場，科學進步、臨床檢驗和商業性實施必須協同一致，才能真正造福患者。該領域的未來不僅取決於機制創新，還取決於組織能力，例如生物標記整合、制定穩健的供應和生產策略，以及建立實現廣泛應用所需的衛生經濟學證據。策略夥伴關係和適應性試驗設計將加速有前景的機制轉化為永續的臨床方案，而針對不同區域的最佳化上市計劃將決定患者接受治療的速度和範圍。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：DNA修復藥物市場：依藥物類別分類

  • ATM抑制劑
  • ATR抑制劑
  • DNA甲基轉移酵素酶抑制劑
  • HDAC抑制劑
  • PARP抑制劑

第9章：依作用機轉分類的DNA修復藥物市場

  • 單株抗體
  • 胜肽
  • 低分子化合物

第10章：DNA修復藥物市場：依適應症分類

  • 乳癌
    • HER2陽性
    • 荷爾蒙受體陽性
    • 三重否定
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第11章 DNA修復藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第12章 DNA修復藥物市場：依最終用戶分類

  • 醫院
  • 藥局
  • 專科診所

第13章 DNA修復藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 DNA修復藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：DNA修復藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國DNA修復藥物市場

第17章：中國DNA修復藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Artios Pharma
  • AstraZeneca PLC
  • Aurigene Discovery Technologies
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Clovis Oncology
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hanson Wade Group
  • Johnson & Johnson Services, Inc.
  • Merck KgaA
  • Novartis AG
  • Pfizer Inc.
  • Valerio Therapeutics
Product Code: MRR-99555D550531

The DNA Repair Drugs Market was valued at USD 9.87 billion in 2025 and is projected to grow to USD 10.53 billion in 2026, with a CAGR of 7.43%, reaching USD 16.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.87 billion
Estimated Year [2026] USD 10.53 billion
Forecast Year [2032] USD 16.31 billion
CAGR (%) 7.43%

Comprehensive orientation to the scientific advancements, regulatory context, and commercial imperatives defining DNA repair therapeutics in contemporary oncology

The DNA repair therapeutics landscape represents a convergence of molecular biology, precision oncology, and novel drug modalities that together are redefining treatment approaches for multiple tumor types. In recent years, therapies targeting DNA damage response pathways have moved from academic curiosity to clinical staples in certain indications, driven by a deeper mechanistic understanding of tumor genomics and synthetic lethality. The field now spans established classes of agents alongside emergent inhibitors that seek to exploit newly discovered vulnerabilities in cancer cells.

This introduction synthesizes the state of play for stakeholders who require a concise, authoritative orientation. It outlines the technological drivers, regulatory context, and commercial considerations shaping development priorities. By placing clinical innovation in the context of operational realities-supply chain resilience, payer engagement, and biomarker deployment-this section equips decision-makers with the baseline perspective needed to interpret subsequent, more granular analyses. Transitioning from scientific promise to routine clinical integration remains the central theme, highlighting the interplay among translational research, regulatory pathways, and commercial strategy.

How genomic precision, adaptive trials, and combination strategies are collectively reshaping development priorities and commercial models across DNA repair therapeutics

The DNA repair therapeutics ecosystem is experiencing transformative shifts that are altering R&D priorities, clinical trial design, and commercial models. Advances in genomic profiling and biomarker validation have compelled developers to design trials that are both molecularly selective and adaptive, enabling faster identification of responders while reducing exposure for non-responders. Concurrently, combination strategies that pair DNA repair inhibitors with immunotherapies, targeted agents, or conventional cytotoxics have matured from exploratory regimens into structured development paths, reflecting a strategic recalibration toward multi-modal approaches.

On the technological front, the rise of next-generation sequencing and liquid biopsy platforms has increased the feasibility of real-time patient selection and monitoring, thereby tightening the feedback loop between clinical outcomes and molecular hypotheses. From a commercial standpoint, payers and health systems are increasingly demanding demonstrable value through biomarker-defined benefit, driving sponsors to integrate health economics and outcomes research earlier in development. As a result of these intersecting forces, the landscape is evolving from single-agent, indication-focused pursuits to more nuanced, mechanism-driven portfolios that emphasize precision, combination potential, and sustainable access models.

Implications of 2025 tariff dynamics on global pharmaceutical supply chains, development timelines, and access strategies for DNA repair therapeutics

Policy shifts involving tariff measures announced or implemented in 2025 have generated renewed attention to cross-border supply chains for pharmaceutical ingredients and finished products. For DNA repair therapeutics-many of which rely on specialized active pharmaceutical ingredients, complex chemical synthesis, and imported laboratory consumables-tariff-driven cost pressures can affect manufacturing economics and the logistics of clinical supply. In response, companies are reassessing supplier diversity, onshoring critical production steps where feasible, and negotiating longer-term procurement contracts to mitigate price volatility.

Beyond immediate cost implications, tariffs interact with regulatory and commercial levers. Higher input costs can prompt adjustments to portfolio prioritization, delaying lower-priority indications or pipeline candidates that require extensive global distribution channels. In parallel, procurement and tender practices among hospitals and health systems may shift toward domestic suppliers or incumbent therapies with established supply resilience, potentially complicating market access for newer entrants dependent on international manufacturing footprints. To navigate this environment, organizations are increasing visibility into tiered supplier risk, enhancing inventory forecasting for pivotal trials, and accelerating localization strategies for manufacturing and quality control infrastructure to sustain development timelines and patient access.

Nuanced segment-driven imperatives showing how drug class, mechanism, indication, route, and end-user dynamics combine to shape distinct development and commercialization strategies

Segment-level insights reveal distinct development pathways and commercial considerations across mechanisms, indications, routes, and end users that collectively define investment priorities. By drug class, the competitive and clinical landscape spans Atm inhibitors, Atr inhibitors, Dna methyltransferase inhibitors, Hdac inhibitors, and Parp inhibitors; within these groups, Dna methyltransferase inhibitors are bifurcated between launched agents and those in the pipeline, while Parp inhibitors present a layered market of branded, generic, and pipeline entrants that influence pricing and positioning strategies. This heterogeneity necessitates differentiated lifecycle approaches: launched agents require label expansion and real-world evidence generation, pipeline candidates demand translational validation and strategic partnerships, and generics call for access and volume-driven tactics.

Considering mechanism of action, therapies based on monoclonal antibodies, peptides, and small molecules exhibit divergent development and commercialization profiles, with small molecules further subdivided into Atm, Atr, Dna methyltransferase, Hdac, and Parp inhibitor chemotypes. The modality influences dosing paradigms, manufacturing complexity, and intellectual property strategies. Indication-focused segmentation highlights breast, ovarian, pancreatic, and prostate cancers as primary therapeutic arenas, with breast cancer further resolved into Her2 positive, hormone receptor positive, and triple-negative subtypes; such granularity drives unique biomarker needs and payer narratives for each subgroup. Route of administration-intravenous, oral, and subcutaneous-affects patient adherence, clinic resource utilization, and homecare opportunities, while end user segmentation across hospitals, pharmacies, and specialty clinics shapes distribution strategies and commercial engagement models. Taken together, these intersecting segments prescribe distinct development roadmaps, go-to-market architectures, and evidence-generation priorities that innovators must reconcile when allocating finite resources.

Regional strategic differentiation across regulatory, reimbursement, and infrastructure realities that determine clinical development priorities and market access approaches

Regional dynamics materially influence strategic decision-making across development, regulatory engagement, and commercialization for DNA repair therapeutics. In the Americas, there is a pronounced emphasis on rapid regulatory engagement, payer evidence generation, and adoption pathways that favor biomarker-driven indications; clinical trial networks and oncology consortia provide a robust environment for late-stage evaluation and real-world evidence capture. Europe, Middle East & Africa present a more heterogeneous landscape where regulatory harmonization, reimbursement diversity, and variable healthcare infrastructure necessitate tailored market entry plans and differentiated pricing strategies. Manufacturers often prioritize countries within the region for early launches based on HTA frameworks and centralized or decentralized reimbursement mechanisms.

Asia-Pacific demonstrates a mix of rapid innovation adoption in select markets and infrastructure-driven constraints in others. Several countries in Asia-Pacific prioritize domestic manufacturing and local clinical data, prompting sponsors to adapt trial designs and commercial models to meet local requirements. Cross-region considerations-such as regional clinical trial enrollment strategies, supply chain routing, and localized evidence generation-play a pivotal role in shaping program timelines and access. Ultimately, regional strategies must balance the imperative for global coordination with the need to localize regulatory, clinical, and commercial approaches to achieve sustainable patient access.

Corporate strategies observed among leading developers focusing on partnerships, diagnostics integration, resilient supply chains, and evidence-driven commercialization to accelerate adoption

Leading companies in the DNA repair therapeutics domain are demonstrating a common set of strategic behaviors: forging collaborative partnerships to expand combination regimens, investing in companion diagnostic development to support precise patient selection, and deploying targeted M&A or licensing activity to shore up complementary assets. Large pharmaceutical firms are increasingly partnering with biotechs to accelerate translational science and to gain access to novel chemotypes or unique biomarker platforms. At the same time, nimble biotechnology companies are leveraging early proof-of-concept data to negotiate co-development deals or to secure capital for pivotal trials, demonstrating an ecosystem where complementary capabilities and shared risk are central to progress.

Commercially, companies are aligning external affairs, medical affairs, and market access functions earlier in development to ensure that evidence generation addresses payer needs. Supply chain resilience and localized manufacturing are emerging as strategic priorities for firms seeking to protect launch timelines against geopolitical and tariff-related headwinds. Finally, the competitive landscape is prompting companies to differentiate through real-world evidence initiatives, patient support programs, and direct engagement with specialist centers to accelerate adoption where clinical benefit is clearest. These tactics collectively reflect a shift toward more integrated, evidence-driven commercialization strategies across incumbent and emerging players alike.

Clear, implementable priorities for leadership to align biomarker-driven evidence, resilient operations, and targeted commercialization for DNA repair programs

Industry leaders should prioritize a set of actionable initiatives that translate scientific promise into durable commercial success. First, integrate biomarker strategies and health economics into early development plans so that trials generate outcomes aligned with payer expectations and clinical decision-making. By doing so, sponsors can reduce time-to-access hurdles and improve value positioning at launch. Second, pursue strategic collaborations that pair complementary mechanisms or modalities to strengthen rationale for combination regimens and to diversify risk across development portfolios.

Third, build supply chain resilience by diversifying API sources, investing in regional manufacturing capacity where justified, and establishing robust inventory planning for pivotal trials. These actions mitigate exposure to tariff shocks and logistical disruptions. Fourth, invest in companion diagnostic partnerships and real-world evidence capture to substantiate effectiveness and to support label expansion efforts. Lastly, tailor regional go-to-market approaches that account for local regulatory, reimbursement, and infrastructure nuances, and deploy targeted stakeholder engagement to accelerate guideline adoption and clinician uptake. Executing these initiatives in a coordinated fashion will improve the likelihood that promising therapeutics transition to widely accessible standards of care.

Robust multi-method research design combining expert primary interviews, comprehensive secondary sources, and triangulated analytical techniques to ensure validity and transparency

This research synthesizes data from a structured multi-method approach combining primary and secondary sources to ensure breadth and depth of insight. Primary research included interviews with key opinion leaders in oncology, executives from small and large biopharmaceutical companies, regulatory specialists, and market access professionals to capture nuanced perspectives on clinical development, regulatory expectations, and commercialization challenges. Secondary research encompassed peer-reviewed literature, clinical trial registries, regulatory filings, patent landscapes, and company disclosures to triangulate findings and validate strategic trends.

Analytical techniques applied include pipeline mapping, competitive landscaping, and scenario-based impact assessment to understand how policy, clinical, and commercial variables interact. Quality controls included source triangulation, expert validation workshops, and a documented audit trail for critical assumptions. The methodology acknowledges limitations related to evolving clinical data and policy changes, and it therefore highlights where findings are most sensitive to new trial outcomes or regulatory developments. Where possible, the analysis emphasizes reproducible methods and transparent rationale so that stakeholders can adapt the approach to their specific decision-making needs.

Concluding synthesis emphasizing the imperative to align mechanistic innovation, evidence generation, and operational resilience to achieve durable clinical and commercial impact

In conclusion, DNA repair therapeutics occupy a pivotal and rapidly evolving niche within oncology where scientific advances, clinical validation, and commercial execution must align to realize patient benefit. The sector's future will be defined not only by mechanistic innovation but also by the ability of organizations to integrate biomarkers, build resilient supply and manufacturing strategies, and generate the health-economic evidence required for broad access. Strategic partnerships and adaptive trial designs will accelerate the translation of promising mechanisms into durable clinical options, while regionally tailored launch plans will determine the speed and extent of patient uptake.

Ultimately, success in this space demands coordinated action across R&D, regulatory affairs, supply chain, and commercial functions. Stakeholders who proactively address evidence generation, payer alignment, and operational resilience will be best positioned to transform scientific opportunity into sustainable therapeutic impact for patients across the major oncology indications served by DNA repair strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Repair Drugs Market, by Drug Class

  • 8.1. Atm Inhibitors
  • 8.2. Atr Inhibitors
  • 8.3. Dna Methyltransferase Inhibitors
  • 8.4. Hdac Inhibitors
  • 8.5. Parp Inhibitors

9. DNA Repair Drugs Market, by Mechanism Of Action

  • 9.1. Monoclonal Antibodies
  • 9.2. Peptides
  • 9.3. Small Molecules

10. DNA Repair Drugs Market, by Indication

  • 10.1. Breast Cancer
    • 10.1.1. Her2 Positive
    • 10.1.2. Hormone Receptor Positive
    • 10.1.3. Triple Negative
  • 10.2. Ovarian Cancer
  • 10.3. Pancreatic Cancer
  • 10.4. Prostate Cancer

11. DNA Repair Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. DNA Repair Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Pharmacies
  • 12.3. Specialty Clinics

13. DNA Repair Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Repair Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Repair Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States DNA Repair Drugs Market

17. China DNA Repair Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Artios Pharma
  • 18.6. AstraZeneca PLC
  • 18.7. Aurigene Discovery Technologies
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. CanBas Co., Ltd.
  • 18.11. Clovis Oncology
  • 18.12. Corden Pharma International GmbH
  • 18.13. Eli Lilly and Company
  • 18.14. Genentech, Inc.
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Hanson Wade Group
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Merck KgaA
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Valerio Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)